Fouad Abbas
Obstetrics & Gynecology · Baltimore, MDNPI 1023087699
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,360 of the $10,883 with a category attached, or 67.6%. 34 manufacturers reported payments, led by Meditrina at 31.9% of the total. Reporting peaked in 2023 at $4,090 and has fallen 82.0% since, to $736 in 2025. Among obstetrics & gynecology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $49.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Meditrina$3K
- Hologic Sales And Service, LLC$835
- Astellas Pharma US Inc$818
- Merck$809
- Sanara Medtech Inc.$729
- AbbVie$717
- plus $4K from 28 others
What the payments were for
- Consulting fees$3,15029%
- Food & beverage$7,36068%
- Education$3553%
- Entertainment$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Meditrina | 4 | $3,472 |
| Hologic Sales And Service, LLC | 9 | $835 |
| Astellas Pharma US Inc | 21 | $818 |
| Merck | 37 | $809 |
| Sanara Medtech Inc. | 7 | $729 |
| AbbVie | 32 | $717 |
| AstraZeneca | 18 | $705 |
| GSK | 13 | $437 |
| Pfizer | 13 | $348 |
| Sumitomo Pharma America, Inc. | 5 | $279 |
| Clovis Oncology, Inc. | 10 | $239 |
| Eisai Inc. | 8 | $230 |
| Intuitive Surgical | 1 | $145 |
| Caldera Medical, Inc | 1 | $130 |
| Seagen Inc. | 4 | $118 |
| Johnson & Johnson(2 entities) | 4 | $83 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $80 |
| Acera Surgical, Inc. | 1 | $78 |
| Baxter Healthcare | 2 | $73 |
| Smith+Nephew | 4 | $73 |
| Myriad Genetic Laboratories, Inc. | 4 | $68 |
| Immunogen, Inc. | 2 | $56 |
| Heron Therapeutics, Inc. | 2 | $41 |
| Medtronic | 2 | $37 |
| Boston Scientific | 1 | $37 |
| Avita Medical Americas, LLC | 2 | $37 |
| Conmed Corporation | 1 | $32 |
| Daiichi Sankyo Inc. | 1 | $30 |
| AMAG Pharmaceuticals, Inc. | 2 | $29 |
| Tesaro, Inc. | 1 | $27 |
| Coopersurgical, Inc. | 1 | $26 |
| Kerecis Limited | 1 | $25 |
| Aesculap, Inc. | 1 | $21 |
| Provepharm Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- aveta$1,050
- CellerateRx$675
- ACESSA PROVU SYSTEM$513
- NovaSure$412
- MYOSURE TISSUE REMOVAL DEVICE$378
- LYNPARZA$242
- Veozah$228
- MYFEMBREE$210
- Da Vinci Surgical System$145
- Desara$130
- Orilissa$117
- ZEJULA$113
- FLUENT FLUID MANAGEMENT SYSTEM$110
- TIVDAK$108
How this compares
$10,883 in reported general payments places this provider in the 95th percentile of 842 obstetrics & gynecology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $7,376 |
| Estradiol | 15 | $977 |
| Fluconazole | 11 | $81 |
| Oxycodone Hcl | 16 | $46 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $348 | $7,37613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 842 obstetrics & gynecology providers in Maryland.
Other obstetrics & gynecology in Baltimore
- Danielle ShillerBaltimore$221K
- Karen WangBaltimore$91K
- Rebecca StoneBaltimore$88K
- Christina EnzmannBaltimore$63K
- Latasha MurphyBaltimore$41K
- Ishrat RafiBaltimore$29K
- Colleen McCormickBaltimore$29K
- Jenell ColemanBaltimore$18K
- David MatthewsBaltimore$12K
- Anne BurkeBaltimore$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.